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Abstract
Patients presenting with thrombocytosis require thorough clinical and laboratory evaluation to determine whether they suffer
from essential thrombocythemia or another myeloproliferative disorder. This distinction becomes increasingly relevant as
targeted agents become available to treat specific myeloproliferative diseases. Cytogenetic testing plays a major role in this
analysis. This study presents a patient with Philadelphia chromosome positive (Ph+ ) thrombocytosis and a cryptic
der(9q)t(5;9)t(9;22) not found by conventional cytogenetics, whose disease progressed within 2 years to typical myeloblastic
crisis of CML. It discusses the entity of Ph+ ET, the utility of molecular cytogenetic testing in the diagnosis of this unusual
disease entity and the importance of cytogenetic testing in the prognosis of ET.
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Introduction
Essential thrombocythemia (ET) is a myeloprolifera-
tive disorder presenting with elevated platelets,
similar to chronic myelogenous leukemia (CML).
The significant overlap in clinical presentation
between CML and ET has led to the wide
acceptance that cytogenetic and molecular analyses
are appropriate in all patients with unexplained
thrombocytosis, although controversies still remain
regarding the appropriate classification of BCR-ABL
fusion positive cases presenting as ET [1]. Whether
these patients are ultimately classified as CML or ET
with a BCR-ABL fusion is less important than the
separation of the ‘BCR/ABL-positive ET’ group of
patients from those with ‘BCR/ABL-negative ET’, as
the natural history of these two disease entities is
distinct [1–3]. A recent review of Ph+ ET noted that
10 of 16 cases terminated in a disease similar to CML
blast crisis [2] and median survival was noted to be
5 – 7 years [1,3], intermediate between CML and ET
[4]. As has clearly been described in previous case
reports and case series, more than half of BCR/ABL-
positive ET patients will progress to the blast phase of
CML [1,2] which has important implications for
treatment and follow-up of this group of patients. In
patients in whom only PCR positivity for BCR/ABL
is found, the disease may not differ from PCR
negative ET [5–7]. However, the diagnosis of Ph+
ET with cytogenetic positive BCR-ABL can be
regarded as an early manifestation of the chronic
stable phase of CML and usually represents a variant
of chronic phase CML [2,3,8]. Cases described as
Ph+ET have normal WBC counts, often a normal
LAP score, rare splenomegaly and may have throm-
botic complications similar to Ph-negative ET, unlike
most patients with chronic phase CML and throm-
bocytosis. The megakaryocytes in Ph+ET and Ph+
thrombocythemia associated with CML are smaller
than normal and typically have hypolobulated nuclei
and this contrasts with the findings of clustered
mature and enlarged megakaryocytes in Ph-negative
ET [8]. These clinical differences highlight the
importance of cytogenetic testing in patients who
present with ET, even though Ph+ET is rare, as
prognosis may be significantly altered by this addi-
tional diagnosis. Specific therapies directed against
the ABL kinase may be appropriate for patients with
Ph+ET with potential relevance for overall prog-
nosis and survival.
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A verified stepwise diagnostic testing algorithm for
the exclusion of the BCR/ABL gene fusion products
in ET has yet to be devised. Similar to CML,
multiple diagnostic modalities may be employed to
exclude the BCR/ABL gene fusion product, includ-
ing traditional karyotype analysis, reverse
transcription-polymerase chain reaction (RT-PCR)
and single fusion or double fusion probe fluorescence
in situ hybridisation (FISH). Recently, FISH capable
of identifying deletions in the derivative chromosome
9 has received attention because such deletions are a
powerful and independent marker for poor prognosis
in CML [9–12], even with the addition of imatinib to
the treatment regimen [13]. This study reports a case
of Ph+ET in a patient with a poor prognosis der(9)
deletion whose disease terminated in a myeloblastic
crisis. The case illustrates the importance of evaluat-
ing patients with thrombocytosis for BCR/ABL and
reinforces the concept that Ph+ET has the potential
to evolve clinically in a fashion more similar to CML
than Ph7ET.
Case history
A 73-year-old man from the Dominican Republic,
with a past medical history significant for hyperten-
sion and no known family history of malignancy,
presented to his physician in the Dominican Repub-
lic in September 2001 when he noticed his toenails
and fingernails appeared black. The patient was
found to be thrombocythemic with a normal WBC
and differential. He was diagnosed with small vessel
thromboses. A sternal bone marrow aspiration was
performed showing myeloproliferation with mega-
karyocytic hyperplasia. Cytogenetic analysis revealed
a 46,XY,t(14;22)(q23;q13) karyotype. The patient
had no splenomegaly and a LAP score was normal. A
diagnosis of essential thrombocythemia was made.
Hydroxyurea treatment was initiated for control of
thrombocytosis. His nail discoloration improved. He
continued with a normal CBC and normal differ-
ential for 18 months.
The patient had no symptomatic complaints when
a routine CBC performed in the spring of 2003
showed a WBC of 32.86 103 cells mL71 (16%
neutrophils, 34% lymphocytes, 20% monocytes,
30% immature appearing monocytoid cells with
basophilic stippling) accompanied by hemoglobin
10.7 g dL71; hematocrit 33.4%; platelets 2626 103
mL71; and mean corpuscular volume (MCV) 113.6
fL. A repeat complete blood count (CBC) 2 weeks
later showed the following: WBC 366 103 cells
mL71 (55% neutrophils, 11% lymphocytes, 11%
monocytes, 13% basophils, 1% bands, 9% blasts);
hemoglobin 11.0 g dL71; hematocrit 33.0%; plate-
lets 2276 103 mL71. Immunophenotyping of bone
marrow aspirate gave the following results: CD13+ ,
CD33+ , CD34+ , CD45+ , HLA-DR+ , CD117+ ,
consistent with acute myeloblastic leukemia (blast
phase of CML).
In July 2003, this patient returned to the US and
presented to the medical center. His CBC at that
time showed: WBC 52.06 103 cells mL71 (25%
neutrophils, 4% lymphocytes, 25% monocytes, 15%
basophils, 2% eosinophils, 30% blasts); hemoglobin
9.9 g dL71; hematocrit 31.5%; platelets 2186
103 mL71. A repeat bone marrow biopsy showed
hypercellularity with myeloproliferation, basophilia
and an increase in immature myeloblasts (*50% of
nucleated cells). A clinical diagnosis of CML in
myeloblastic crisis was made and cytogenetic studies
were performed. Systemic chemotherapy was in-
itiated. The patient obtained a hematologic remission
and was subsequently treated with imatinib. He
relapsed with blastic disease 5 months later and
succumbed to complications of his disease.
Materials and methods
Cytogenetic studies
Metaphase preparations were made by standard
methods and analyzed on G-banded preparations.
Twenty metaphases were analyzed and the karyotype
was described by standard ISCN nomenclature.
Spectral karyotype (SKY) analysis was performed
on metaphase preparations using a human SkyPaint
Probe kit obtained from Applied Spectral Imaging
(Carlsbad, CA, USA) according to the manufac-
turer’s protocol. SKY images were acquired with a
SD300 Spectra cube mounted on a Nikon Eclipse
800 microscope by using a SKY optical filter
(Chroma Technology, Brattleboro, VT, USA) and
analyzed using SKY View software.
FISH was performed using BCR/ABL dual color,
dual fusion (D-FISH) probe combined with an
Aqua-labeled ASS probe mapped proximal to ABL
at 9q34 (both probes were obtained from VYSIS,
Downers Grove, IL, USA). Hybridization was
performed using standard methods. Hybridization
signals were analyzed on a Nikon Eclipse 600
microscope attached to a CytoVision imaging system
(Applied Imaging, Santa Clara, CA, USA).
Results
Cytogenetic studies
Cytogenetic analysis done elsewhere on bone marrow
mononuclear cells at initial presentation in 2001
revealed an unequivocal 46, XY,t(14;22)(q23;q13)
karyotype. Cytogenetic testing performed in
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July 2003 upon presentation to the medical center
revealed a 46,XY,t(14;22)(q23;q13)[8]/46,XY,
idem,t(13;17)(q12;q22)[9]/47,XY,idem, + 8[3] kar-
yotype (Figure 1(a)) and immunohistochemical
studies were positive for CD33, CD13, CD117,
CD64, CD11c, HLA-DR and MPO antigens. To
examine whether this complex karyotype was the
result of variant Ph+ chromosome, a spectral
karyotype (SKY)analysiswasperformed(Figure1(b)).
A combined G-banding and SKY karyotype
of 47,XY, +8,der(9)t(5;9)(?;q34),t(13;17)(q12;q22),
del(14)(q23),ins(22;14)(q13.1;q24q32)[cp25] was
derived and present in all metaphases, which
provided no direct evidence for the existence of
a BCR/ABL gene fusion. A deletion of 14q was
recognised, as what was thought to be a translocation
of 14;22 by G-banding was discovered to be
ins(22;14) by SKY. Based on a high clinical index
of suspicion for CML, FISH was also performed
using a dual color, dual fusion BCR/ABL probe to
look for the presence of a Ph+ chromosome It was
observed that 99.5% of the inter-phase cells studied
shows a pattern of two orange signals (one with
highly reduced signal), one green signal and one
fusion signal, consistent with the presence of the
BCR-ABL gene fusion product (Ph+ chromosome)
and deletion of the reciprocal partner. Analysis of
metaphase chromosomes showed that the BCR/
ABL fusion signal was present on the ins(22;14)
chromosome and a reduced spectrum orange signal
Figure 1. (a) A G-banded karyotype showing 46,XY,+8,t(13;17)(q12;q22),t(14;22)(q23;q13). Arrows indicate abnormal chromosomes.
(b) A SKY karyotype showing 47,XY,+8,der(9),t(5;9)(?;q34),t(13;17)(q12;q22),del(14)(q23),ins(22;14)(q13.1;q24q32). Abnormalities are
indicated.
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on der(9) chromosome. This pattern of signals was
suggestive of the presence of BCR/ABL fusion of the
t(9;22) and a deletion on the der(9)t(5;9) involving
the 30BCR sequence,. To confirm the deletion on
der(9), FISH was also performed using the 9q (ASS)
probe combined with BCR/ABL probe (Figure 2).
The ASS probe was present as a residual signal on
the der(9) chromosome, suggesting a large part of the
gene is deleted. This result again confirms the
presence of a deletion on der(9). All metaphase and
interphase cells with BCR/ABL fusion showed the
same pattern; The experiment was replicated and
both times scored by two different investigators.
Overall, these results are suggestive of deletion of the
most part of ASS gene, 50 part of the ABL gene and
the 30 BCR sequence. Based on these results, a
diagnosis of CML, with a cryptic BCR-ABL fusion
and der(9) deletion, presenting with a clinical
thrombocythemic onset was made.
RT-PCR for BCR-ABL
To confirm the presence of a standard BCR/ABL
translocation, RNA was extracted from the patient’s
white cells using TriazolTM and 2 mg of patient RNA
was reverse transcribed using Superscript M-MLV
reverse transcriptase, followed by 2 rounds of PCR
using previously published primers for the P210
transcript. The result was positive for the typical
chimeric message.
Discussion
Essential thrombocythemia is a diagnosis of exclu-
sion. It is a clonal myeloproliferative disorder which
is limited to the megakaryocytic series. ET has
clinical heterogeneity, with many patients having a
relatively benign course over many years. It is rare
to find chromosomal abnormalities in ET, esti-
mated to be present in only 5 – 10% of cases by
metaphase cytogenetics [14]. The Ph+ chromo-
some is the most commonly found abnormality and
there is considerable evidence that Ph+ET may
represent a ‘forme fruste’ of early chronic phase
CML. CML is a chronic myeloproliferative disorder
defined by the presence of the Ph+ chromosome, a
chromosomalderivativeformedbythereciprocaltrans-
location of the long arms of chromosomes 9 and
22. This characteristic translocation takes place
between the 5’ end of the breakpoint cluster region
(BCR) gene located at 22q11.2 and the 3’ end of
the c-ABL proto-oncogene (ABL1) located at 9q34,
forming a BCR-ABL fusion gene that has a
constitutively active Abl tyrosine kinase [15]. The
Ph+ chromosome is seen during standard cytoge-
netic analysis in 85 – 95% of cases of CML, with
the remaining 5 – 15% of cases showing variant
Ph+ chromosomes or cryptic BCR-ABL rearrange-
ments [16–21]. Case reports have described a
translocation t(14;22), similar, but not identical to
that seen in the patient, as both a simple and
complex Philadelphia chromosome variant [22–24].
A number of studies have suggested that these
variant translocations have prognostic importance
[11,25]. As cytogenetic analysis can miss up to 10%
of cases of CML, molecular tests for the BCR-ABL
fusion product have been developed for use when
a Ph+ chromosome cannot be identified. Southern
blotting [26], RT-PCR and FISH [27,28] have
all been used to identify the BCR-ABL gene
rearrangement.
The patient was found to have a pattern of 2
orange signals, 1 green signal and 1 fusion signal by
D-FISH. The solitary green signal and one of
the solitary orange probes represent copies of the
BCR and ABL genes on the normal chromosomes
9 and 22, respectively. The fusion probe is consistent
with the presence of a BCR-ABL fusion gene on the
derivative chromosome ins(22;14). The classic
t(9;22) normally creates a reciprocal ABL-BCR
fusion which is seen in the D-FISH assay as a second
fusion signal on the derivative chromosome 9
[29,30]. In this patient, the second solitary orange
probe seen on der(9) represents the 50ABL portion
of the reciprocal fusion, without the expected
30BCR. The lack of a third green signal suggests that
this region of genetic material has been deleted in
Figure 2. A metaphase showing FISH signals using BCR/ABL dual
color, dual fusion probe (BCR, spectrum green; ABL, spectrum
orange) combined with ASS probe mapped to 9q34 (Spectrum
aqua). Normal chromosome 9 showing an ABL (orange) and ASS
(aqua) signals together at 9q34. Normal chromosome 22 showing
BCR signal (green). Arrow indicates the presence of BCR/ABL
(green and orange) signals together on derivative chromosome 22.
Arrowhead indicates the reduced signals of ABL (orange) and ASS
(aqua) on der(9) chromosome.
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the multiple recombination events which formed the
cryptic BCR-ABL fusion and complex karyotype
seen in the patient. The dual fusion FISH probes
reduce the false positive rate to almost zero for
identifying the reciprocal fusion product [31–33].
However, the use of the dual fusion probe led to the
observation that a significant number of patients with
clinically apparent CML lacked all or part of the
reciprocal fusion product [12]. These studies have
revealed that deletions on der(9) are a powerful and
independent marker for poor prognosis in CML
[9–11]. In the present case the prognostic implications
of a derivative chromosome 9 deletion also appear to
be negative.
Dual color, dual fusion FISH thus offers both
diagnostic and prognostic information in patients
with suspected CML. Since survival differences in
patients with der(9) deletions appear to be partially
abrogated when patients are treated with imatinib
[13], the test provides useful treatment information
as well. However, the limitation of FISH is that it
does not identify the presence of an active bcr-abl
tyrosine kinase in the cell. A possible mechanism
by which the der(9) deletions may confer a more
severe phenotype may be the loss of ABL-BCR
transcript. Since the FISH probes range from
300–650 kb in size, small, but clinically important,
deletions may not be detected with this system.
The prognostic relevance of such deletions has not
been rigorously studied and published reports
indicate that loss of ABL-BCR transcript alone does
not confer a poor prognosis [34,35]. It is of interest
that SKY analysis was unable to identify this complex
translocation.
The analysis was confounded by a complex
chromosomal rearrangement that lacked the recipro-
cal fusion product normally found on derivative
chromosome 9 which would also have suggested
the presence of a derivative BCR/ABL rearrangement.
Cytogenetic abnormalities in ET are rare and it is
believed this is the first report of a patient
with Ph+ET, showing a deletion on der(9) with a
variant Ph+ chromosome. The clinical behavior of
the patient in this case report suggests that this
syndrome behaves more like CML than ET, in
particular with the poor prognosis of those CML
patients with der(9) Ph+ variants, even with imatinib
therapy. Since a functional BCR-ABL gene product
is theoretically possible with the insertion of less
than 350 kB of DNA, more specific identification
of any clinically suspected BCR/ABL rearrange-
ment in patients with ET must be investigated with
molecular techniques such as dual color, dual fusion
FISH. The findings in this patient argue for cyto-
genetic and FISH testing of all patients with suspected
ET.
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